Scientists peek inside lung tumors to outsmart drug resistance

NCT ID NCT03042221

Recruiting now Knowledge-focused Sponsor: University of Colorado, Denver Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at why some lung cancer cells survive targeted treatment. Researchers will take small tissue samples (biopsies) from 100 patients before and two weeks after starting therapy. By comparing the samples, they hope to find early signs of resistance and identify ways to block it, leading to better combination treatments in the future.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALK GENE MUTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALK GENE MUTATION BRAF V600E EGFR GENE MUTATION NON-SMALL CELL CARCINOMA OF LUNG, TNM STAGE 4 NON-SMALL CELL LUNG CANCER ROSE CLUSTER 1

Contacts and locations

Locations

University of Colorado, Cancer Center
RECRUITING

Aurora, Colorado, 80045, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.